Finerenone is also a very welcome addition to our growing armamentarium, as we get closer to a guideline directed medical therapy for DKD, which would include an ACE-I or ARB, MRA, SGLT2 inhibitors, and possibly a GLP-1 agonist. Here, GCG is linked to diabetic kidney disease.